A
Andrzej Madej
Publications - 3
Citations - 144
Andrzej Madej is an academic researcher. The author has contributed to research in topics: Bacterial pneumonia & Pneumonia. The author has an hindex of 2, co-authored 3 publications receiving 102 citations.
Papers
More filters
Journal ArticleDOI
Omadacycline for Community-Acquired Bacterial Pneumonia
Roman Stets,Monica Popescu,Joven Gonong,Ismail Mitha,William Nseir,Andrzej Madej,Courtney Kirsch,Anita Das,Lynne Garrity-Ryan,Judith N. Steenbergen,Amy Manley,Paul B. Eckburg,Evan Tzanis,Paul C. McGovern,Evan Loh +14 more
TL;DR: Omadacycline was noninferior to moxifloxacin for the treatment of community‐acquired bacterial pneumonia in adults and investigator‐assessed clinical response at a post‐treatment evaluation 5 to 10 days after the last dose.
Journal ArticleDOI
A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study)
Roman Stets,Monica Popescu,Joven Gonong,Ismail Mitha,William Nseir,Andrzej Madej,Courtney Kirsch,Anita Das,Lynne Garrity-Ryan,Judith N. Steenbergen,Amy Manley,Paul B. Eckburg,Stephen Villano,Evan Tzanis,Paul C. McGovern,Evan Loh +15 more
TL;DR: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Patients With CABP (The OPTIC Study).
Journal ArticleDOI
2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)
Andrzej Madej,John Pullman,Monica Popescu,Megan Quintas,Laura Lawrence,Yang Li,Sue Cammarata +6 more
TL;DR: DLX may offer a promising alternative in the treatment of CABP including elderly patients and had comparable outcomes to MOX in clinical success at TOC, and was well tolerated regardless of age or gender.